Thursday, October 9

(The presenters of gray titles did not allow the online appearance of their lectures )

56. CANCER METABOLISM AND AUTOPHAGY

ROOM A, 08.00-12.00 – Thursday, October 9

Chair Persons: R. Clarke, J. Holst

Inhibiting autophagy as a strategy to improve antiestrogen responses in breast cancer. K. Cook, A. Wärri, D. Soto-Pantoja, P. Clarke, I. Cruz, A. Zwart, R. Clarke (Washington, DC; Bethesda, MD, USA) (40’)
Nutrient regulation coordinates adaptive cancer cell metabolism. J. Holst (Camperdown, NSW, Australia) (40’)
MAPK15 mediates BCR-ABL-induced autophagy and cellular transformation. D. Colecchia, M. Chiariello (Siena, Italy) (30’)
Modulation of colon cancer cell lipidome and kinetics by dietary fatty acids. J. Hofmanova (Brno, Czech Republic) (30’)
LC3A vs. LC3B: two distinct autophagosome markers to consider for experimental and translational studies. M.I. Koukourakis (Alexandroupolis, Greece) (30’)
The autophagic responce to photodynamic therapy. B. Ziólkowska, M. Wozniak, K. Dus – Szachniewicz, P. Ziólkowski (Wroclaw, Poland) (10’)
Transcription factor EB (TFEB) sustains migratory phenotype of lung cancer cell lines. D. Kalamida (Alexandroupolis, Greece) (20’)

57. INVASION AND METASTASIS

ROOM A, 13.00-16.15 – Thursday, October 9

Chair Persons: J. Carlsson, M. Schauer

Imaging of HER2-expression in breast cancer metastases. J. Carlsson (Uppsala, Sweden) (30’)
Tissue factor, VCAM-1 and VAP-1 orchestrate the recruitment of macrophages to tumour cells in pulmonary metastasis. A. Gil-Bernabe (Oxford, Oxfordshire, UK) (40’)
Direct participation of the metastasis suppressor NME1 in DNA repair pathways. D.M. Kaetzel, G. Cook, S. Jarrett, M.J. Leonard, M. Novak, A. Greenawalt (Baltimore, MD, USA) (30’)
Positioning LMTK3 on the map of oncogenic signaling cascades and elucidating its role in invasion and metastasis in Breast Cancer. G. Giamas, Y. Xu, H. Zhang, C. Vorgias, J. Stebbing (London, UK) (20’)
Molecular mechanisms for local invasion and metastases of gastric cancer. Do tyrosine receptors play a role? M. Schauer (Duesseldorf, Germany) (20’)
Modified adipose mesenchymal progenitors target ewing’s sarcoma. G. Grisendi, C. Spano, N. D’Souza, V. Rasini, E. Veronesi, S. Piccinno, G. De Santis, E. Horwitz, P. Conte, P. Paolucci, M. Dominici (Modena; Padova, Italy; Philadelphia, PA, USA) (20’)

58. APOPTOSIS

ROOM A, 16.30-19.15 – Thursday, October 9

Chair Persons: B. Kaina, M. I. Panagiotidis

Apoptosis, autophagy and DDR triggered by temozolomide. B. Kaina, A. Knizhnik, A. Krumm, M. Eich, W.P. Roos (Mainz, Germany) (30’)
Regulation of mitotitc death. T.C. Chambers (Little Rock, AR, USA) (40’)
BMX negatively regulates BAK function increasing apoptotic resistance to chemotherapeutic agents in cancer cells. J. Fox, A. Storey (Oxford, UK) (15’)
Resistance to UV-induced apoptosis by beta HPV5 E6 involves targeting of activated BAK for proteolysis by recruitment of the HERC1 ubiquitin ligase. A. Holloway, M. Simmonds, A. Azad, J. Fox, A. Storey (Oxford, UK) (15’)
Hormonally induced apoptosis, related to androgen and GNRH receptor status in prostate cancer. An overview. B. Szende, I. Romics, J. Szabó, G. Bánfi, T. Krenács (Budapest, Hungary) (15’)
Hyperthermia-induced cell death in human malignant melanoma. T. Mantso, A. Sfakianos, M.J. Cañavate Sánchez, A. Pappa, G. Goussetis, M. Panagiotidis (Edinburgh, UK; Alexandroupolis, Greece) (15’)

59. NEW ANTICANCER AGENTS

ROOM B, 08.00-14.30 – Thursday, October 9

Chair Persons : A. Z. Dudek, M. Schneider

Kiteplatin – a potential clinical candidate showing significant activity vs. oxaliplatin-resistant colorectal cancer. J.D. Hoeschele, E. Petruzzella, N. Margiotta, G. Natile, V. Gandin and C. Marzano (Ypsilanti, MI, USA; Bari; Padova, Italy) (30’)
Opportunities and challenges to develop drugs for treating glioblastoma: A mechanistic prospective. A. Bhushan, A. Jain, J.C.K. Lai (Philadelphia ; Lexington ; Pocatello, USA) (30’)
Metal-based anticancer agents basing on TCM active ingredient oxoisoaporphine alkaloids. Z.F. Chen, Q.P. Qin, J.L. Qin, Y.C. Liu, K.B. Huang, Y. Peng, H. Liang (Guilin, P.R. China) (30’)
HSV1716 (SEPREHVIR): an oncolytic herpes virus for cancer therapy. L. Braidwood (Glasgow, UK) (30’)
Targeted drug delivery to pediatric sarcomas through proprotein convertases binding peptides. P. Jaaks, M. Roveri, V. D’Alessandro, B.W. Schäfer, P. Luciani, M. Bernasconi (Zurich, Switzerland) (20’)
A promising novel palladium-saccharinate complex of terpyridine against cancer stem cells. E. Ulukaya (Nilüfer, Bursa, Turkey) (15’)
Anticancer activity of novel Vitamin D analogs: structural and functional insights. N. Rochel (Illkirch, France)(20’)
Conjugation of anti-cancer drug to phage carrying anti-mica for targeting chemotherapy. A. Phumyen, S. Jantasorn, A. Jumnainsong C. Leelayuwat (Khon Kaen, Thailand) (10’)
Alkaloids mixture affects ENT1 and DCK gene expression in pancreatic ductal adenocarcinoma (PDAC): synergistic interaction with gemcitabine in preclinical models of PDAC. N. Funel, L.E. Pollina, G. Genova, U. Boggi, D. Campani (Pisa; Pontedera, Italy) (15’)

Chair Persons: M. I. Panagiotidis, E. Ulukaya

Virotherapy with VSV-INFβ for non-small cell lung cancer. M.R. Patel, B.A. Jacobson, K. Xiong, S. Tang, H. Wang, Y. Ji, A. Kratzke, S.J. Russell R.A. Kratzke (Minneapolis, MN, USA) (10’)
Copper(II) complexes of 5-(pyridin-2-yl)-norhydrastinine: crystal structure, cytotoxicity and interaction with DNA. K.B. Huang, Z.F. Chen, Y.C. Liu H. Liang (Guilin, P.R. China) (15’)
Synthesis and antitumor mechanism of a new anthracene imidazole hydrazone derivative. Y.C. Liu, H.L. Wang, S.F. Tang, Z.F. Chen, H. Liang (Guilin, P.R. China) (15’)
Isothiocyanates as anticancer agents in an in vitro model of human malignant melanoma. A. Sfakianos, T. Mantso, S. Tabaczar, A. Pappa, M. Panagiotidis (Edinburgh, UK; Alexandroupolis, Greece) (10’)
Mafosfamide and glufosfamide as new anticancer oxazaphosphorine agents. L. Mazur, M. Opydo-Chanek, M. Stojak, K. Sladowska, K. Blicharski, B. Janota, U. Niemeyer (Krakow, Poland; Bielefeld, Germany) (15’)

60. ADVANCES IN PROSTATE CANCER

ROOM B, 14.45-19.00 – Thursday, October 9

Chair Persons : K. De Meirleir, D. Sliva

Late events in chemotherapy-treated prostate cancer patients: Circulating LDH, CgA and CrP values. P. Bouffette, S. Buhic, K. Kovacic, M. Tarle (Dubrovnik; Zagreb, Croatia) (20’)
Relationship between signalling cross-talksbetween the epidermal growth factor receptor (EGFR), c-Met and c-Src and prostate tumour cell response to clinical tyrosine kinase inhibitors. S. Rao, A.L. Larroque-Lombard, B. Allal, J. Jean-Claude Bertrand (Montreal, Canada) (30‘)
Will extreme hypofractionation in prostate radiotherapy improve clinical outcome? A. Dasu, I. Toma-Dasu (Linköping, Sweden) (15’)
Mistakes in prostatic carcinoma assessment on multiparametric 3t mri: non-pirads and pirads evaluation versus whole-mount section histology. J. Ferda, J. Kastner, E. Ferdová, J. Baxa, R. Fuchsová, M. Hora, O. Hes, O. Topolcan (Pilsen, Czech Republic) (15’)
How the war on cancer was lost: strategies for winning. A.A. Sinha (Minneapolis, MN, USA) (40’)

Chair Persons: A. A. Sinha, M. Tarle

Anticancer effect of prosta caid: A research overview from laboratory to clinical response. D. Sliva, I. Eliaz (Indianapolis, IN; Santa Rosa, CA, USA) (30’)
Stereotactic body radiotherapy in prostate cancer: where are we going? B. De Bari, L. Lestrade, F. Alongi (Lausanne; Geneva, Switzerland; Negrar; Verona, Italy) (20’)
Vitamin D deficiency in patients with prostate cancer. K. Wieczorek, R.S. Braczkowski, B. Braczkowska (Katowice, Poland) (15’)
Prostate-specific antigen variations in Moroccan patients with histologically proven benign prostatic hyperplasia. I. Sadaoui, W. Mahfoud, H. Amrani Hassani Joutei, N. Elgnaoui, A. Seddiki, H. Benomar, S. Nadifi (Casablance, Morocco) (15’)
NF- κB nuclear localization and its prognostic in Moroccan patients with hormono-refractory prostate cancer. I. Sadaoui, V. Brrès, B. Péant, H. Amrani Hassani Joutei, W. Mahfoud, H. Benomar, A.-M. Mes Masson, F. Saad, S. Nadifi (Casablanca, Marocco, Montreal, QC, Canada) (15’)

61. DIAGNOSIS AND PROGNOSIS OF CANCER

ROOM C, 08.00-15.15 – Thursday, October 9

Chair Persons: F. Lumachi, R. Nagler, D. Schiffer

Chair Persons: R. Andersson, K. Guzinska-Ustymovicz

Salivary tumor markers for oral and oropharyngeal cancer. R. Nagler (Haifa, Israel) (30’)
The Digital Cancer Patient. C. Sansom, V. Diaz-Zuccarini (London, UK) (20’)
Nuclear receptors in pancreatic tumorcells. C. Damaskos, T. Karatzas, I.D. Kostakis, L. Nikolidakis, A. Kostakis, G. Kouraklis (Athens, Greece) (10’)
Proteomics approaches to identifying proteins involved in adenoma-to-colorectal carcinoma progression. K. Dus-Szachniewicz, P. Ostasiewicz, P. Ziólkowski, M. Wozniak, B. Ziólkowska, M. Mann, J.R. Wisniewski (Wroclaw, Poland) (10’)

Chair Persons: P. Dziegiel, C. Sansom

Invasive micropapillary carcinoma as a new histological type of adenocarcinomas in the colorectal cancer. K. Guzinska-Ustymowicz, K. Niewiarowska, A. Pryczynicz (Bialystok, Poland) (10’)
Predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFT therapy? N. Marchoudi, H. Amrani Hassani Joutei, F. Jouali, J. Fekkak, H. Rhaissi (Mohammedia; Casablanca, Morocco) (15’)
Assessment of shoulder and neck dysfunction and functional status post radiotherapy/chemotherapy in head and neck cancer patients: a pilot study. P.K. Ghotra, S. Saini, A. Malhotra(Ludhiana, India) (15’)
Cancer communication: Researchers, doctors, patients and the worried well. C. Sansom (London, UK) (15’)
IGF1 serum levels in malignant melanoma and healthy subjects. R. Kucera, I. Treskova, J. Vrzalova, S. Svobodova, O. Topolcan, R. Fuchsova, V. Treska, T. Kydlicek (Prague, Czech Republic) (15’)
Association between Fuhrman grade and IGFs family genes expression in clear cell renal cell carcinoma. R.S. Braczkowski, M. Bialozyt, B. Braczkowska, L. Dul(Bytom; Katowice, Poland) (15’)

62. RADIOTHERAPY

ROOM C, 15.30-17.30 – Thursday, October 9

Chair Persons: L. Trigo, N. Nguyen

Accelerated partial breast irradiation (APBI) with multicatheter interstitial brachytherapy over 11 years of practice. A. Aguiar, L. Trigo, N. Stas (Porto, Portugal) (20’)
High-dose irradiation do not modify the immunosuppressive effects elicited by cancer-associated fibroblasts. T. Hellevik, L. Gorch, T.B. Stuge, I. Martinez-Zubiaurre (Trømso, Norway) (20’)
The impact of radiation oncology evolution on the incidence of radiation induced cranial nerves palsy in patients with head and neck cancer. W.F. Mourad (New York, NY, USA) (30’)
Treatment of refractory cancer pain: what can we expect from image guided interventional techniques? B. Kastler, H.Alnassan, X. Wang, A. Kastler (Besançon, France) (20’)

63. ADVANCES IN BREAST CANCER

ROOM D, 8.00-12.00 – Thursday, October 9

Chair Persons: J.E. Slansky, A.M. Cimpean, G. Broich

Analysis of the T-cell receptor repertoire in breast cancer using emusion single cell RT-PCR. D.J. Munson, T.C. Bruno, B.L. Moore, V.F. Borges, J.W. Kappler, J.E. Slansky (Aurora, CO; Portland, OR, USA) (30’)
Decreased expression and/or mutation of FRY, a promoter of epithelial cell differentiation, is associated with epithelial mesenchymal transition and clinical progression of breast cancer. H. Zarbl, N. Takizawa, J. Graham, B. Estrella, Z. Gong, X. Ren (Piscataway; North Brunswick, NJ; Buffalo, NY, USA) (30’)
Progress in the care for hereditary breast cancer: A twenty year anniversary. J. De Grève (Brussels, Belgium) (30’)
Social isolation stress induces obesity and unfolded protein response and autophagy in the mammary gland, and increases mammary tumorigenesis in mice. K. Cook, A. Sumis, E. Kidney, F. Andrade, R. Hu, X. Zhang, W. Yu, K.B. Bouker, R. Clarke, L. Hilakivi-Clarke (Washington, DC, USA; São Paulo, Brazil) (30’)
Canine mammary tumour: A spontaneous animal model for human breast cancer. B. Restucci (Naples, Italy)(30’)
Joint effects of genes, body constitution, and lifestyle: exploring novel pathways to predict prognosis and response to therapy in breast cancer. H. Jernström (Lund, Sweden) (30’)
Metabolomic profile of triple negative breast cancer in African American women reveals potential biomarkers of aggressive disease. Y.M. Kanaan, B.P. Sampey, D. Beyene, T.J. Naab, A.K. Esnakula, K.W. Blackman, L. Ricks-Santi, S. Dasi, Agnes Day, W. Frederick, R.L. Copeland, E. Gabrielson, R.L. DeWitty (Washington, DC, USA) (30’)

64. ADVANCES IN BREAST CANCER

ROOM D, 13.00-17.30 – Thursday, October 9

Chair Persons: L. Hilakivi-Clarke, M. Eskelinen

Breast brachytherapy fixation system: plastic tubes technique. L. Trigo, N. Stas (Porto, Portugal) (30’)
Vaccines for primary prevention of breast cancer. K.L. Knutson (Port St Lucie, FL, USA) (30’)
Targeted intraoperative radiation therapy – Advances In local therapy of breast cancer. W. Malter, V. Kirn, K. Rogee, L. Richters, P. Mallmann, S. Kraemer (Cologne, Germany) (20′)
Individual xenograft for women with metastatic triple negative breast carcinoma: a step toward personalized medicine. G. Bousquet, A. Janin (Paris, France) (20’)
Identify variant EPOR forms expressed in human breast cancers. Z. Rakosy, G. Paragh, G. Acs (Wauwatosa, WI; Tampa, FL, USA) (10’)
The potential benefit of scanned proton beam versus intensity modulated photon therapy as adjuvant radiation therapy in breast cancer. A. Dasu, A.M. Flejmer, F. Dohlmar, D. Josefsson, P. Witt Nyström (Linköping, Sweden) (15’)
Adult weight gain and breast density. C. Diorio (Quebec, QC, Canada; Carouge, Switzerland) (20’)

Chair Persons: A. Dasu, M. Raica

New aspects concerning the radiation of breast cancer. E. Bölke, C. Matuschek, W. Budach (Düsseldorf, Germany) (30’)
AAA vs PBC for treatment planning of breast cancer from the perspective of the National Swedish Breast Cancer Group recommendations. A.M. Flejmer, F. Dohlmar, M. Nilsson, M. Stenmarker, A. Dasu (Linköping, Sweden) (15’)
Evaluation of predictive markers for clinical outcome after neoadjuvant radiochemotherapy in breast cancer. C. Matuschek, H.B. Prisack, W. Audretsch, E. Bölke, C.N. Krämling, W. Budach, H. Bojar (Düsseldorf, Germany) (15’)

65. NEW INSIGHTS IN BRAIN TUMORS
Special Symposium Organized by G. Sica and M. Jhanwar-Uniyal

ROOM E, 8.00-12.00 – Thursday, October 9

Chair Persons: G. Sica, M. Jhanwar-Uniyal

Genomic heterogeneity in glioblastoma: An overview of its clinical and therapeutic implications. S.C. Jhanwar (New York, NY, USA) (25’)
New strategies in the study of glioblastoma: A neurosurgical point of view. A. Mangiola, P. De Bonis, N. Saulnier, L. Lauriola, G. Lama, D. Orteschi, M. Zollino, M. Jhanwar-Uniyal, G. Maira, C. Anile, G. Sica (Rome, Italy) (25’)
Characterization of cancer stem cells derived from glioblastoma and peritumor tissue. G. Sica , G. Lama, A. Colabianchi, A. D’Alessio, G. Proietti, C. Angelucci, B.M. Scicchitano, A. Mangiola, E. Binda, A. Vescovi, G. Maira (Rome, Italy) (25’)
Glioblastoma multiforme: finding novel inhibitors for effective and selective targeting. J. L. Gillick, R. Murali, M. Jhanwar-Uniyal (Valhalla, NY) (25’)
Adult mouse sub-ventricular zones stimulate glioblastoma stem cells specific invasion through CXCL12/CXCR4 signaling. N. Goffart, J. Kroonen, E. Di Valentin, M. Dedobbeleer, A. Denne, P. Martinive, B. Rogister (Liege, Belgium; Utrecht, The Netherlands) (20’)
An integrated view of the transcriptome and miRNome of glioblastoma and peritumor tissues. B. Fazi, D. Sicari, S. Galardi, M.G. Farace, G. Maira, P. De Bonis, C. Anile, A. Mangiola, S.A. Ciafré (Rome, Italy) (30’)

66. CANCER PREVENTION IN ASIA PACIFIC COUNTRIES
Special Symposium of the Asian Pacific Organization for Cancer Prevention (APOCP),
Organized by C.-H. Yip and C.-J. Chen

ROOM E, 13.00-16.00 – Thursday, October 9

Chair Persons: C.-J. Chen, C.-H. Yip

Cancer burden in the asia pacific region – trends and future challenges. J. Dunn (Brisbane, Australia) (25’)
Regional players in cancer control in Asia. M.A. Moore (Bangkok, Thailand) (30’)
National cancer screening program and improvement in cancer survival. in Korea. K.-Y. Yoo (Seoul, South Korea) (15’)
Prevention of breast cancer in Asia. C.H. Yip (Selangor, Malaysia) (30’)
Role of civil society organisations in cancer control. J. Dunn (Queensland, Australia) (25’)

67. TOXICOLOGY AND CANCER AETIOLOGY
Special Symposium of the Asian Pacific Organization for Cancer Prevention (APOCP),
Organized by C.-H. Yip and C.-J. Chen

ROOM E, 16.15-18.30 – Thursday, October 9

Chair Persons: C.-J. Chen, C.-H. Yip

Cancer prevention by control of infectious agents through immunization and therapy. C.J. Chen (Taipei, Taiwan) (30’)
Prevention strategy of adult t-cell leukemi/lymphoma by htlv-1 eradication. K. Tajima (Mie, Japan) (20’)
Ingested bovine lactoferrin promotes immune system responsiveness to inhibit carcinogenesis. D. B. Alexander, M. Iigo, H. Hamano, K. Yamauchi, J. Xu H. Tsuda, M.A. Moore (Bangkok, Thailand; Nagoya; Zama, Japan) (30’)
Epidemiology, screening and vaccination of HPV and cervical cancer in China. Y.L. Qiao (China) (20’)
Epidemiology of schistosomiasis and urinary bladder cancer in Egypt after the national schistosomiasis control programs. E. I. Salim (Tanta, Egypt) (15’)

68. NATURAL PRODUCTS IN CANCER DRUG DEVELOPMENT
Special Symposium Organized by B. Littlefield

ROOM F, 08.00-12.00 – Thursday , October 9

Chair Persons: B. Littlefield, M. Hamann

Defining a new protein target for the selective treatment of melanoma. W. Fenical, L. Trzoss, J. LaClair, L.V. Costa-Lotufo, P. Jimenez (San Diego, CA, USA; Fortaleza, Brazil) (40′)
Screening natural product libraries for cancer-selective cytotoxins. D. Demers, M. Knestrick, C. Witowski, J. Von Salm, R. Green, L. Hamel, M. Howell, C. Powell, A. Ubaldani, L. Calcul, L. Chen, D. Mitchell, Y. Ren, B. Vesely, R. Deschenes, D.E. Kyle, S. Mohapatra, S. Westerheide, J. Wu, B.J. Baker (Tampa, FL, USA) (30′)
Inhibition of spontaneous and induced mutagenesis by natural compounds and mixtures. P.G. Sacks, Z.L. Zhao, W. Kosinska, Z. He, M. Khmelnitsky, J.H. Kim, J.B. Guttenplan (New York, NY, USA) (15′)
The taccalonolides: plant derived microtubule stabilizers. S.L. Mooberry, A.L. Risinger, J. Peng, C.C. Rohena, J. Li, A.R.B. Ola, J. Kuhn (San Antonio, TX, USA) (40′)
Patemine A and congeners: Anticancer strategies with protein synthesis inhibitors. D. Romo (College Station, TX, USA) (40′)
Dietary constituents and experimental breast cancer. G. Vollmer, O. Zierau, B.M. Dietz, J.L. Bolton, G.F Pauli, D. Macejova (Dresden, Germany; Chicago, IL, USA; Bratislava, Slovak Republic) (15′)
A glimpse into natural product drug discovery at Eisai. M.H.D. Postema (Andover, MA, USA) (40′)

69. NATURAL PRODUCTS IN CANCER DRUG DEVELOPMENT
Special Symposium Organized by B. Littlefield

ROOM F, 13.00-17.30 – Thursday , October 9

Chair Persons: S. Moobery, D. Romo

Taxol, tubulin and tumors. S.B. Horwitz (Bronx, NY, USA)(40’)
Discovery and development of anticancer lead compounds from marine Cyanobacteria. W. Gerwick (La Jolla, CA, USA) (30′)
Chemical and biological syntheses of polyketide regulators of proteostasis. R.E. Taylor (Notre Dame, IN, USA) (40′)
EGFR inhibition by curcumin in cancer cells: a dual mode of action. M. Starok, P. Preira, M. Vayssade, K. Haupt, L. Salomé, C. Rossi (Compiègne; Toulouse, France) (10′)
Structural specificity of genin flavonoids suppresses the commotion of aromatase and cathepsin D, pivotal targets for breast cancer. S. Luqman, V. Dubey, N. Masood (Lucknow, India) (10′)
Chemistry and biology of the marine natural product psymberin. J.K. De Brabander (Dallas, TX, USA) (40′)
Studies of anti-cancer activities of naturally occurring terpene extracted from the seeds of Pithcellobium dulce plant. S.H. Ganatra, A. Ramteke (Nagpur, India)